

BDR PHARMACEUTICALS INTERNATIONAL PVT. LTD.

TERMINATION LETTER

Date: May 17, 2023

To, MEDICINES PATENT POOLRue de Varembe 7, Geneva 1202,
Switzerland

Kind Attention: Chan Park, General Counsel

Subject: Termination of the License Agreement dated January 13, 2022 executed between BDR Pharmaceuticals International Private Limited ("BDR") and Medicines Patent Pool ("MPP").

Dear Sir,

- (a) This letter ("Termination Letter") is in reference to the License Agreement dated January 13, 2023 as amended by Amendment to the License Agreement dated July 01, 2022 between BDR and MPP ("License Agreement") for licensing a non-exclusive, non-transferable, non-sublicensable license under the Territory Patents and MSD Know-How to manufacture the Product at a facility that is in the Territory.
- (b) BDR hereby informs that BDR is desirous of terminating the License Agreement due to lack of demand for the Product and commercial viability. Consequently, pursuant to rights conferred under the License Agreement, with effect from expiry of 30 (thirty) days from the date of this Termination Letter. the License Agreement shall stand terminated.
- (c) The provisions of Clause 12.5 (*Notices*), Clause 12.6 (*Language; Governing Law*), Clause 12.7 (*Dispute Resolution*) and Clause 12.9 (*Amendment*) of the License Agreement shall apply *mutatis mutandis* to this Termination Letter as if the same were set out in full herein, and form part of this Termination Letter.

All capitalized terms used herein shall have the meaning given to such term in the License Agreement.

For and on behalf of BDR Pharmaceuticals International Private Limited

Name: Mr. Tejash Shah

Designation: Director

Registered Office: 407/408, Sharda Chambers, New Marine Lines, Mumbai - 400020, INDIA.

CIN No.: U24230MH2002PTC137329